Just a smallish reminder, here...

Last week, the relevant FDA Advisory Committee indicated it was not likely to recommend that the full FDA approve a Merck cough therapy, due to uneven evidence of efficacy, and some side effect profiles, in some study participants.

Technically, the committee asked for more data, but this likely means the drug won't reach US markets, as a practical matter.

This is true, because it was never going to be a juggernaut (so Rahway may elect to stop spending on more clinical trials for it).

As such, it just was never going to be material to a $60 billion a year by revenue company. It just. . . won't ever be. And the loss of any future revenue from a non-approval. . . similarly won't move any needles. So -- the general reminder (in case you weren't reading here five years ago when I last made this sort of a PSA!): we won't comment on immaterial Merck matters, at all. As a rule. Now you know. Onward, grinning. . . be excellent to one another.

नमस्ते